Charles River Laboratories Has Potential to Outperform in 2H 2026, RBC Says

MT Newswires Live06-05

Charles River Laboratories (CRL) has the potential to outperform expectations in the second half of 2026, RBC Capital Markets analysts said in a Thursday note.

Analysts said that the company's "Pathways to Purpose" strategy is positioning it to capitalize on improving biotech funding and pharma investment in research and development.

RBC said that the company sees various opportunities, including in China, New Alternative Methods, and organic market share gains from a recent competitor's bankruptcy.

"We expect strong biopharma funding to continue in 2026 which combined with healthy cash runways should manifest in accelerated preclinical R&D spending growth in 2026 and into 2027," analysts said.

RBC has an outperform rating and a $215 price target on the stock.

Price: 184.94, Change: -0.85, Percent Change: -0.46

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2641514677?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-05 22:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2641514677","market":"hk","top_or_hot":-1,"title":"Charles River Laboratories Has Potential to Outperform in 2H 2026, RBC Says","media":"MT Newswires Live","content":"<html><body><p> Charles River Laboratories (CRL) has the potential to outperform expectations in the second half of 2026, RBC Capital Markets analysts said in a Thursday note.</p><p>Analysts said that the company's \"Pathways to Purpose\" strategy is positioning it to capitalize on improving biotech funding and pharma investment in research and development.</p><p>RBC said that the company sees various opportunities, including in China, New Alternative Methods, and organic market share gains from a recent competitor's bankruptcy.</p><p>\"We expect strong biopharma funding to continue in 2026 which combined with healthy cash runways should manifest in accelerated preclinical R&amp;D spending growth in 2026 and into 2027,\" analysts said.</p><p>RBC has an outperform rating and a $215 price target on the stock.</p><p>Price: 184.94, Change: -0.85, Percent Change: -0.46</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Charles River Laboratories Has Potential to Outperform in 2H 2026, RBC Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCharles River Laboratories Has Potential to Outperform in 2H 2026, RBC Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-05 22:53</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Charles River Laboratories (CRL) has the potential to outperform expectations in the second half of 2026, RBC Capital Markets analysts said in a Thursday note.</p><p>Analysts said that the company's \"Pathways to Purpose\" strategy is positioning it to capitalize on improving biotech funding and pharma investment in research and development.</p><p>RBC said that the company sees various opportunities, including in China, New Alternative Methods, and organic market share gains from a recent competitor's bankruptcy.</p><p>\"We expect strong biopharma funding to continue in 2026 which combined with healthy cash runways should manifest in accelerated preclinical R&amp;D spending growth in 2026 and into 2027,\" analysts said.</p><p>RBC has an outperform rating and a $215 price target on the stock.</p><p>Price: 184.94, Change: -0.85, Percent Change: -0.46</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CRL","symbol_name":"查尔斯河","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2641514677","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2641514677","pubTimestamp":1780671236,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Charles River Laboratories  has the potential to outperform expectations in the second half of 2026, RBC Capital Markets analysts said in a Thursday note.Analysts said that the company's \"Pathways to Purpose\" strategy is positioning it to capitalize on improving biotech funding and pharma investment in research and development.RBC said that the company sees various opportunities, including in China, New Alternative Methods, and organic market share gains from a recent competitor's bankruptcy.\"We expect strong biopharma funding to continue in 2026 which combined with healthy cash runways should manifest in accelerated preclinical R&D spending growth in 2026 and into 2027,\" analysts said.RBC has an outperform rating and a $215 price target on the stock.Price: 184.94, Change: -0.85, Percent Change: -0.46","collect":0,"end_time":0,"defaultTopTitle":"","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"CRL":"查尔斯河"},"translate_title":"加拿大皇家银行表示，Charles River Laboratories有潜力在2026年下半年跑赢大盘","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRL":1.5},"content_text":"Charles River Laboratories (CRL) has the potential to outperform expectations in the second half of 2026, RBC Capital Markets analysts said in a Thursday note.Analysts said that the company's \"Pathways to Purpose\" strategy is positioning it to capitalize on improving biotech funding and pharma investment in research and development.RBC said that the company sees various opportunities, including in China, New Alternative Methods, and organic market share gains from a recent competitor's bankruptcy.\"We expect strong biopharma funding to continue in 2026 which combined with healthy cash runways should manifest in accelerated preclinical R&D spending growth in 2026 and into 2027,\" analysts said.RBC has an outperform rating and a $215 price target on the stock.Price: 184.94, Change: -0.85, Percent Change: -0.46","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2641514677","isCrawlerRequest":true}